The Melanocortin System: MC3R, MC4R, and CNS-Mediated Pathways

POMC is processed by tissue-specific prohormone convertases to yield α-MSH, β-MSH, γ-MSH, and ACTH — each with distinct receptor selectivity profiles. α-MSH (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂) is the primary endogenous agonist at MC1R, MC3R, and MC4R, with lower potency at MC2R and MC5R.

MC1R is expressed primarily in melanocytes and mediates pigmentation. MC2R is the ACTH receptor in the adrenal cortex. MC3R and MC4R are expressed in the hypothalamus and limbic system and are the primary mediators of melanocortin effects on energy balance and autonomic function. MC5R is expressed in exocrine glands.

MC4R is one of the most important regulators of energy homeostasis in mammals. MC4R knockout mice develop severe obesity, hyperphagia, and hyperinsulinemia — a phenotype that has been replicated by pharmacological MC4R antagonism. Conversely, MC4R agonism reduces food intake and increases energy expenditure.

The MC4R is expressed on POMC neurons in the arcuate nucleus and on neurons in the paraventricular nucleus (PVN) of the hypothalamus. PVN MC4R activation increases sympathetic nervous system activity, promoting thermogenesis and lipolysis. This makes MC4R a key node connecting central melanocortin signaling to peripheral metabolic effects.

PT-141 is a cyclic analog of α-MSH (cyclo[Nle4, D-Phe7]-α-MSH) that acts as a non-selective melanocortin agonist with activity at MC1R, MC3R, MC4R, and MC5R. It was developed from Melanotan II and is notable for its CNS-mediated mechanism — unlike peripherally acting compounds, PT-141 crosses the blood-brain barrier and acts centrally.

Pfaus et al. (2004) demonstrated that PT-141 activates dopaminergic pathways in the medial preoptic area (MPOA) of the hypothalamus in rats, providing a mechanistic basis for its CNS-mediated effects. The FDA approved bremelanotide (Vyleesi) in 2019 for hypoactive sexual desire disorder in premenopausal women, validating the CNS melanocortin pathway as a therapeutic target.

PT-141's non-selectivity across MC receptor subtypes is both a strength and a limitation as a research tool. For studying the integrated melanocortin system response, broad agonism is informative. For dissecting the contributions of individual receptor subtypes, selective agonists or antagonists (e.g., SHU9119 for MC3R/MC4R antagonism) are preferred.

Researchers using PT-141 should be aware of its effects on blood pressure (transient increases via MC1R/MC3R-mediated mechanisms) and nausea (via area postrema MC4R), which can confound behavioral endpoints in rodent studies.